S&P ASX All Technology

US Dollar vs AUD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

GLYC GlycoMimetics Inc

1.8399

0.1199 (6.97%)

04 May 2024 - Closed

Delayed by 15 minutes

GlycoMimetics says first patient dosed in investigator-sponsored mid-stage uproleselan study

To read the full story on Seeking Alpha, click here.

GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more GlycoMimetics Charts.

GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more GlycoMimetics Charts.

GlycoMimetics Inc News

GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024
Thursday 25 April 2024 (1 week ago) • Business Wire

GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
Wednesday 27 March 2024 (1 month ago) • Business Wire

GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024
Wednesday 13 March 2024 (2 months ago) • Business Wire

Form 8-K - Current report
Saturday 2 March 2024 (2 months ago) • Edgar (US Regulatory)

GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference
Monday 26 February 2024 (2 months ago) • Business Wire

GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Monday 12 February 2024 (3 months ago) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 18 January 2024 (4 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 18 January 2024 (4 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 18 January 2024 (4 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 18 January 2024 (4 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 18 January 2024 (4 months ago) • Edgar (US Regulatory)

GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687
Thursday 4 January 2024 (4 months ago) • Business Wire

More GlycoMimetics Inc News Articles

Gold vs US Dollar

Australian SE All Ordina...

Westpac Banking

S&P ASX 300 Metals and M...

National Australia Bank

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions